London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here


Come to London

video-icon

WATCH to find out why


Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Intraocular lens explantation/exchange: indications

Poster Details

First Author: R.Oltulu TURKEY

Co Author(s):    I. Ersan   G. Satirtav   M. Donbaloglu   H. Kerimoglu   A. Ozkagnici  

Abstract Details

Purpose:

This study was performed to analyze the indications for explantation/exchange of intraocular lenses (IOL), which had originally been implanted for the correction of aphakia during cataract extraction.

Setting:

Necmettin Erbakan University Meram Faculty of Medicine, Ophthalmology Clinic.

Methods:

All cases that have undergone IOL explantation/exchange, in one institution between January 2008 and December 2014 were analyzed retrospectively.

Results:

A total of 93 eyes of 93 patients were analyzed. Pseudophakic bullous keratopathy (17 eyes, 38.6%) and persistent iritis (12 eyes, 27.8%) in anterior chamber (AC) IOL group, and dislocation/decentration (30 eyes, 61.2%) and incorrect IOL power (9 eyes, 18.4%) in posterior chamber (PC) IOL group were the most common indications for explantation of IOLs. The mean LogMAR best corrected visual acuity (BCVA) had improved significantly from preoperative 1.30 to postoperative 0.62 in PC IOL group (p<0.001), but had not improved significantly in AC IOLs group (p=0.186)

Conclusions:

In conclusion, careful patient selection, appropriate surgical technique, optimally selected IOL power measurements based on precise biometry readings as well high quality of IOL materials are the most important factors in minimizing the risk for IOL explantation. Despite these measures, if an IOL extraction/exchange is needed, it should be known that it has favorable outcomes.

Financial Disclosure:

NONE

Back to Poster listing